Evidence map›Paper›PMID 38835240›Full record

ArticleOpen biology2024

Amyloidogenic regions in beta-strands II and III modulate the aggregation and toxicity of SOD1 in living cells.

Luke McAlary, Jeremy R Nan, Clay Shyu, Mine Sher, Steven S Plotkin, Neil R Cashman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luke McAlaryDjavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-1764-3809
Jeremy R NanDjavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Clay ShyuDjavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Mine SherDjavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Steven S PlotkinDepartment of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada.
Neil R CashmanDjavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.

Funding

Brain CanadaCanadian Consortium for NeurodegenerationCIHRR. Howard Webster Foundation
6 · The paper itself

Abstract

Mutations in the protein superoxide dismutase-1 (SOD1) promote its misfolding and aggregation, ultimately causing familial forms of the debilitating neurodegenerative disease amyotrophic lateral sclerosis (ALS). Currently, over 220 (mostly missense) ALS-causing mutations in the SOD1 protein have been identified, indicating that common structural features are responsible for aggregation and toxicity. Using

Indexed as

Amyotrophic Lateral SclerosisProtein AggregatesSuperoxide Dismutase-1AmyloidHumansModels, MolecularMutationProlineProtein Aggregation, PathologicalProtein Conformation, beta-StrandProtein FoldingAmyloidProlineProtein AggregatesSOD1 protein, humanSuperoxide Dismutase-1amyloidamyotrophic lateral sclerosisprotein aggregationprotein homeostasisSOD1

Identifiers

PMID38835240
PMCPMC11285818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.